Viral Filtration Market

Report Overview

The global viral filtration market was pegged at US$ 9.4 billion in 2021 and is expected to witness a CAGR of 10% during the forecast period.

Market Fundamental 

Viral filtration uses a membrane barrier to keep virus particles in place and provides a crucial line of defence against unforeseen viruses. The safety of biopharmaceutical medicinal products will greatly depend on pharmaceutical corporations' increased spending in virus filtration. Market players anticipate that North America and Europe will continue to be the two largest markets as they continue to invest in cutting-edge technologies.

[87624824]

Market Dynamic 

The adoption of single-use technologies, increase in viral contamination of treatments, rise in R&D spending, and government backing are factors propelling the global virus filtration market. However, a highly consolidated market and strict laws governing the validation of filtering products limit market expansion. Outsourcing in the pharmaceutical industry and developing nations are signs of potential growth for this market. Additionally, the market is expanding as a result of factors including the rising prevalence of chronic diseases. The market for biologics is expected to increase due to the rising prevalence of chronic diseases such cancer, diabetes, and autoimmune disorders.

Market Ecosystem 

The global viral filtration market has been analysed by four perspective product, technology application, and region.

Viral Filtration Market Product

Based on product, the global viral filtration market has been segmented into consumable, instruments, and services. The consumable is sub-segmented into kits and reagents and others whereas instruments is also sub-segmented into filtration system and chromatography system. The consumable segment dominated the market during forecast period. because these products are being used more often for viral filtration. Consumables such reagents, kits, and membranes are likely to see an increase in demand as more attention is paid to developing vaccines, protein treatments, blood products, cellular therapy products, gene therapy products, tissue products, and stem cell products.

Viral Filtration Market Technology

Based on product, the global viral filtration market has been segmented into filtration, chromatography. The filtration segment dominated the segment during forecast period due to the increased use of these goods in research, medical device manufacturing, and the production of biologics. Additionally, it offers a number of benefits including not denature the proteins in the product or sample and excellent efficacy and purity on both a small- and large-scale operation.

Viral Filtration Market Application

[2413123]

Based on product, the global viral filtration market has been segmented into biologicals, stem cell products, medical devices, water purification, air purification. The biologicals are sub-segmented into vaccine and therapeutics, blood and blood products, cellular and gene therapy products and tissue & tissue products. The biological segment dominated the market during forecast period. This can be linked to the rising incidence of chronic diseases that increase demand for biologics, such as growth hormone deficiency, blood disorders, cancer, diabetes, and autoimmune disorders.

Viral Filtration Market End User 

Based on end user, the global viral filtration market has been segmented into biopharmaceuticals and biotechnology, contract research organisation, medical devices company, and academic institutes and research laboratories. The biopharmaceuticals and biotechnology segment dominated the market during forecast period due to rising R&D efforts, biologics output, and expansion of the biopharmaceutical industry. Additionally, in the United States, Germany, the United Kingdom, Japan, China, and India, viral filtration technology is widely used. Having large biopharmaceutical and biotechnology companies nearby, having a strong healthcare system, and having access to cutting-edge products are some of the main drivers of growth in these nations.

Viral Filtration Market Region

Based on product, the global viral filtration market has been segmented into North America, Europe, Asia Pacific, and rest of the World. North America dominated the global market, and this dominance is anticipated to continue over the forecast period. The established biotechnology and biopharmaceutical sectors in the United States have increased the region's demand for improved viral clearance products for research and development and biologics manufacturing. Due to the significant demand for novel virus filtration products for research and the development and manufacturing of biologics, Europe was the second-largest market. The region's market is also anticipated to be driven by highly developed healthcare infrastructure and significant investments in R&D, particularly in Germany, the United Kingdom, and France.

During the forecast period, Asia Pacific is anticipated to have the highest CAGR due to an increase in the number of trauma cases and traffic accidents. According to estimates, the region's growth will be fuelled by the existence of untapped growth prospects in the quickly expanding Asian economies of China, India, and Indonesia.

Competitive Landscape 

Some of the prominent market players in the global viral filtrations market 

• Merck KGaA
• Asahi Kasei Corporation
• BioProcess International
• Sartorius AG
• General Electric
• Thermo Fisher Scientific, Inc.
• General Electric Company
• PendoTECH
• Lonza
• Charles River Laboratories
• Sotera Health
• WuXi AppTec. 

Strategic Development 

• In January 2021, With Charles River Laboratories, one of the world's top providers of laboratory services, SenzaGen renewed and expanded its global collaboration arrangement with this business. The agreement was expanded to encompass all tests available in the GARD portfolio in order to fulfil the rising demand for risk assessment of chemicals utilising SenzaGen's non-animal test platform GARD.
• In June 2021, Lonza announced its partnership with Moderna, a biotechnology firm that developed the first messenger RNA vaccines and medicines. The extended agreement will allow for more COVID-19 Vaccine Moderna medicinal substance manufacturing. At Lonza's Geleen facility, a new manufacturing line for the synthesis of drug substances will be made available.
• In October 2019, Asahi Kasei Medical acquired ViruSure. The acquisition was carried out by Asahi Kasei Medical as part of the organization's growth and reinforcement strategy. The objective was to further strengthen the company's bioprocess business, which is focused on PlanovaTM virus removal filters, by utilising ViruSure's cell banking services and biosafety testing services.

Frequently Asked Questions About This Report